May 7, 2019, HemOnc Today 

Physicians may be able to predict which patients with HER2-positive breast cancer can safely forgo surgery based on tumor hormone status, imaging results after neoadjuvant chemotherapy and ductal carcinoma in situ on initial biopsy, according to study results presented at American Society of Breast Surgeons Annual Meeting.  

Read more.